Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Tycho Peterson - Jefferies Andrew Brackman - William Blair Doug Schenkel - Wolfe Research Dan Brennan - Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Dan Arias - Stifel Jack Meehan - Nephron Research Patrick Donnelly - Citi Dan Leonard - UBS Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Hello. At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 Earnings Conference Call.
Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook
Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results. The post Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook appeared first on Investor's Business Daily.
Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade
Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
Can This Beaten-Down Cathie Wood Stock Bounce Back?
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
FMR LLC Bolsters Stake in Exact Sciences Corp
On September 30, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, significantly increased its investment in Exact Sciences Corp (EXAS, Financial), a leader in cancer diagnostics. The firm acquired an additional 8,418,428 shares at a price of $68.12 each, elevating its total holdings to 22,042,464 shares.
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
